Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
actinium (225Ac) ibu-dab-psma
- Development stage
- Discontinued
- Lead developer
- ITM Isotope Technologies Munich
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Actinium (225Ac) Ibu-DAB-PSMA (also known as [225Ac]Ac-SibuDAB) is an investigational targeted alpha therapy (TAT) developed by ITM Oncologics for the treatment of PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). The compound consists of the alpha-emitting radioisotope Actinium-225 conjugated to a small-molecule PSMA ligand that has been modified with an ibuprofen-based albumin-binding moiety ('Ibu') and a diaminobutyric acid (DAB) linker. This design is intended to extend the drug's circulation time in the blood, thereby enhancing tumor uptake and therapeutic efficacy compared to first-generation radioligands. Although it entered Phase I clinical development, the trial was withdrawn before completion.
- Other names
- Actinium (225Ac) Ibu-DAB-PSMAActinium-225 Ibu-DAB-PSMAActinium225 Ibu-DAB-PSMAActinium 225 Ibu-DAB-PSMA[225Ac]Ac-SibuDAB
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on actinium (225Ac) ibu-dab-psma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on actinium (225Ac) ibu-dab-psma.